Third Time's The Charm: Outlook Therapeutics Lytenava Heads To FDA, Again [Seeking Alpha]
Outlook Therapeutics, Inc. (OTLK)
Last outlook therapeutics, inc. earnings: 2/14 08:00 am
Check Earnings Report
Company Research
Source: Seeking Alpha
My bullish stance is underpinned by the NORSE EIGHT trial, conducted under Special Protocol Assessment, and improved manufacturing controls addressing prior FDA concerns. OTLK reported initial Lytenava revenues in Europe, but maintains a high cash burn, with roughly four months of runway and a $139M enterprise value. A negative FDA outcome could trigger a 50–70% sell-off, while approval would validate the strengthened regulatory package and drive forward U.S. commercialization prospects. Milan Markovic/iStock via Getty Images Thesis Outlook Therapeutics ( OTLK ) has had a pretty rough 2025. The company, despite having Lytenava approved in the UK and EU, has struggled in recent years to get the FDA on their side. So far, it has resulted This article was written by Analyst's Disclosure: I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initiate any such positions within the next 72 hours. I wrote this article myse
Show less
Read more
Impact Snapshot
Event Time:
OTLK
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
OTLK alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
OTLK alerts
High impacting Outlook Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
OTLK
News
- Outlook Therapeutics Announces New Employment Inducement Grants [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics Announces New Employment Inducement GrantsGlobeNewswire
- Oncobiologics (NASDAQ:OTLK) had its price target raised by analysts at Ascendiant Capital Markets from $8.00 to $10.00. They now have a "buy" rating on the stock.MarketBeat
- Outlook Therapeutics Reports Financial Results for Fiscal Year 2025 [Yahoo! Finance]Yahoo! Finance
- Outlook Therapeutics Reports Financial Results for Fiscal Year 2025GlobeNewswire
OTLK
Earnings
- 8/14/25 - Miss
OTLK
Sec Filings
- 12/19/25 - Form 10-K
- 12/19/25 - Form 8-K
- 11/3/25 - Form 8-K
- OTLK's page on the SEC website